Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22

Sleeping agent Zolpidem 5 200, 4 doses ↑ 28% ↑ 22% Zolpidem and ritonavir may be co-administered with careful monitoring for excessive sedative effects.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zolpidem (HOS-086327)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d09d3bfcffec89f6d5ec1820b0f813ba45d6f6481d613eb811eda1cac2c70887 · Zeichen 54475–54772 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55

HOS-086488 · Präparat HOS-083284

Sleeping agent Zolpidem 5 200, 4 ↑ 28% ↑ 22% doses Zolpidem and ritonavir may be co-administered with careful monitoring for excessive sedative effects.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zolpidem (HOS-086327)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage b17b75acec5321daa06be2a95d364456562a161822d82a863eb9fc1dbf8f3b11 · Zeichen 56825–57223 im Abschnitt

Wechselwirkungen · Xyrem

Xyrem 500 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 7

HOS-113657 · Präparat HOS-093953

Sedative hypnotics Drug interaction studies in healthy adults with sodium oxybate (single dose of 2.25 g) and lorazepam (single dose of 2 mg) and zolpidem tartrate (single dose of 5 mg) demonstrated no pharmacokinetic interactions. Increased sleepiness was observed after concomitant administration of sodium oxybate (2.25 g) and lorazepam (2 mg). The pharmacodynamic interaction with zolpidem has not been assessed. When higher doses up to 9 g/d of sodium oxybate are combined with higher doses of hypnotics (within the recommended dose range) pharmacodynamic interactions associated with symptoms of CNS depression and/or respiratory depression cannot be excluded (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lorazepam (HOS-085981) zolpidem (HOS-086327) zolpidem tartrate (HOS-113658)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-05-12T16:47:00Z · SHA-256 458b7a20ee31b89a8296f6c62f1482472a82c1e2139396dca882dd3f5b361fd3 · Passage 98dba599e7e0dc91ad52eea57669c625d058cefaa54c8305756ea187b12284c6 · Zeichen 405–1089 im Abschnitt

Wechselwirkungen · Circadin

Circadin 2 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4

HOS-115821 · Präparat HOS-094361

 Alcohol should not be taken with Circadin, because it reduces the effectiveness of Circadin on sleep.  Circadin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics, such as zaleplon, zolpidem and zopiclone. In a clinical trial, there was clear evidence for a transitory pharmacodynamic interaction between Circadin and zolpidem one hour following co-dosing. Concomitant administration resulted in increased impairment of attention, memory and co-ordination compared to zolpidem alone.  Circadin has been co-administered in studies with thioridazine and imipramine, active substances which affect the central nervous system. No clinically significant pharmacokinetic interactions were found in each case. However, Circadin co-administration resulted in increased feelings of tranquility and difficulty in performing tasks compared to imipramine alone, and increased feelings of “muzzy- headedness” compared to thioridazine alone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) thioridazine (HOS-086281) zolpidem (HOS-086327) zaleplon (HOS-115822) zopiclone (HOS-115824)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-07-07T15:22:00Z · SHA-256 3017f870241dac3ebcc1e9e3316286f78f9cbb94c80634571ffcb14a78331107 · Passage 0e406d4ad6632ada4055b0a88989ef86091edd2aa13d8a7c6cc10414f1e5128c · Zeichen 2494–3540 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 23–24

HOS-116425 · Präparat HOS-094447

23 For the treatment of Not studied. Concomitant use of A safe and effective dose of pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of hypertension pulmonary arterial hypertension and pulmonary arterial hypertension Sildenafil boosted PREZISTA may increase plasma co-administered with boosted Tadalafil concentrations of sildenafil or tadalafil. PREZISTA has not been (CYP3A inhibition) established. There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope). Therefore, co-administration of boosted PREZISTA and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with boosted PREZISTA is not recommended. PROTON PUMP INHIBITORS Omeprazole # Boosted PREZISTA can be darunavir AUC ↔ 20 mg once daily # darunavir Cmin ↔ co-administered with proton pump # darunavir Cmax ↔ inhibitors without dose adjustments. SEDATIVES/HYPNOTICS Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is Clorazepate extensively metabolised by CYP3A. recommended when Diazepam Co-administration with boosted co-administering boosted Estazolam PREZISTA may cause a large increase in PREZISTA with these Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower Midazolam (parenteral) dose of the sedatives/hypnotics Zolpidem should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9634d5188deeb063704d3dec6fa9fde3f4c10970d03131c50c223d1e001e36d7 · Zeichen 72803–75985 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 65–66

HOS-116532 · Präparat HOS-094447

65 For the treatment of Not studied. Concomitant use of A safe and effective dose of pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of hypertension pulmonary arterial hypertension and pulmonary arterial hypertension Sildenafil darunavir co-administered with low dose co-administered with PREZISTA Tadalafil ritonavir may increase plasma and low dose ritonavir has not concentrations of sildenafil or tadalafil. been established. There is an (CYP3A inhibition) increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope). Therefore, co-administration of PREZISTA with low dose ritonavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with PREZISTA and low dose ritonavir is not recommended. PROTON PUMP INHIBITORS Omeprazole # PREZISTA co-administered with darunavir AUC ↔ 20 mg once daily # darunavir Cmin ↔ low dose ritonavir can be # darunavir Cmax ↔ co-administered with proton pump inhibitors without dose adjustments. SEDATIVES/HYPNOTICS Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is Clorazepate extensively metabolised by CYP3A. recommended when Diazepam Co-administration with co-administering PREZISTA with Estazolam PREZISTA/ritonavir may cause a large these sedatives/hypnotics and a Flurazepam increase in the concentration of these lower dose of the Midazolam (parenteral) medicines. sedatives/hypnotics should be Zolpidem considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) ritonavir (HOS-084521) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d55e033062b465321f1e7d6496fca1203bde2ceee842c6b87a58cc57f689d470 · Zeichen 63956–67534 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 105–106

HOS-116621 · Präparat HOS-094447

105 PROTON PUMP INHIBITORS Omeprazole # Boosted PREZISTA can be darunavir AUC ↔ 20 mg once daily # darunavir Cmin ↔ co-administered with proton pump # darunavir Cmax ↔ inhibitors without dose adjustments. SEDATIVES/HYPNOTICS Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is Clorazepate extensively metabolised by CYP3A. recommended when Diazepam Co-administration with boosted co-administering boosted Estazolam PREZISTA may cause a large increase in PREZISTA with these Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower Midazolam (parenteral) dose of the sedatives/hypnotics Zolpidem should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage a73d9af50672fdd14c65bde9d86094db034ee45f6e6d86b95e800c8a40b7c035 · Zeichen 74475–75820 im Abschnitt

Wechselwirkungen · Xtandi

Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 6

HOS-127857 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3973–4850 im Abschnitt

Wechselwirkungen · Xtandi

Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36

HOS-127925 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3974–4851 im Abschnitt

Wechselwirkungen · Zydelig

Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-132115 · Präparat HOS-097192

Buspirone, clorazepate, ↑ serum concentrations Concentration monitoring of diazepam, estazolam, sedatives/hypnotics is recommended flurazepam, zolpidem and dose reduction may be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) flurazepam (HOS-086166)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage 7c4a66355000a66b0c38db8012a4bef0ca7498b9174907a0d2021212a7cee0a4 · Zeichen 13200–13501 im Abschnitt

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20

HOS-134030 · Präparat HOS-097520

19 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas levels. co-administration with Genvoya Mean percent change in AUC, Cmax, Cmin1 Tricyclic antidepressants (TCAs) Interaction not studied with any of Careful dose titration of the Trazodone the components of Genvoya. antidepressant and monitoring for Selective serotonin reuptake antidepressant response is inhibitors (SSRIs) Concentrations of antidepressant recommended. Escitalopram agents may be increased when co-administered with cobicistat. IMMUNOSUPPRESSANTS Ciclosporin Interaction not studied with any of Therapeutic monitoring is Sirolimus the components of Genvoya. recommended upon Tacrolimus co-administration with Genvoya. Concentrations of these immunosuppressant agents may be increased when administered with cobicistat. SEDATIVES/HYPNOTICS Buspirone Interaction not studied with any of Co-administration of Genvoya and Clorazepate the components of Genvoya. triazolam is contraindicated (see Diazepam section 4.3). With other Estazolam Triazolam is primarily metabolised sedatives/hypnotics, dose reduction Flurazepam by CYP3A. Co-administration may be necessary and concentration Lorazepam with Genvoya may result in monitoring is recommended. Triazolam increased plasma concentrations of Zolpidem this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) lorazepam (HOS-085981) diazepam (HOS-085904) zolpidem (HOS-086327) serotonin (HOS-085477) trazodone (HOS-086251) tacrolimus (HOS-085202) buspirone (HOS-086325) sirolimus (HOS-085172) escitalopram (HOS-129417) triazolam (HOS-086168) flurazepam (HOS-086166)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 5942209e475c796ef61c4b0bb67f6fad6953705ca4043b5a69de6960506043d8 · Zeichen 46301–48689 im Abschnitt

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21–22

HOS-134522 · Präparat HOS-097580

21 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Geometric mean change Recommendations concerning co- therapeutic areas (%) administration For the treatment of Not studied. Concomitant use of A safe and effective dose of pulmonary arterial sildenafil or tadalafil for the treatment sildenafil for the treatment of hypertension of pulmonary arterial hypertension and pulmonary arterial hypertension co- Sildenafil darunavir co-administered with low administered with darunavir and Tadalafil dose ritonavir may increase plasma low dose ritonavir has not been concentrations of sildenafil or tadalafil. established. There is an increased (CYP3A inhibition) potential for sildenafil- associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope). Therefore, co- administration of darunavir with low dose ritonavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with darunavir and low dose ritonavir is not recommended. PROTON PUMP INHIBITORS Omeprazole # darunavir AUC ↔ Darunavir co-administered with low 20 mg once daily # darunavir Cmin ↔ dose ritonavir can be co- # darunavir Cmax ↔ administered with proton pump inhibitors without dose adjustments. SEDATIVES/HYPNOTICS Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is Clorazepate extensively metabolised by CYP3A. recommended when co- Diazepam Co-administration with administering darunavir with these Estazolam darunavir/ritonavir may cause a large sedatives/hypnotics and a lower Flurazepam increase in the concentration of these dose of the sedatives/hypnotics Midazolam medicines. should be considered. (parenteral) Zolpidem If parenteral midazolam is co- If parenteral midazolam is co- administered with darunavir co- administered with darunavir with administered with low dose ritonavir it low dose ritonavir, it should be may cause a large increase in the done in an intensive care unit (ICU) concentration of this benzodiazepine. or similar setting, which ensures Data from concomitant use of close clinical monitoring and parenteral midazolam with other appropriate medical management in protease inhibitors suggest a possible case of respiratory depression 3-4 fold increase in midazolam plasma and/or prolonged sedation. Dose levels. adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) ritonavir (HOS-084521) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4418dc5e5d870dbdffdec96577360a7846fd09dd38b08120ab6e36d180a150e5 · Zeichen 64193–68705 im Abschnitt

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63–64

HOS-134634 · Präparat HOS-097580

63 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Recommendations concerning co- therapeutic areas Geometric mean change (%) administration For the treatment of Not studied. Concomitant use of A safe and effective dose of sildenafil pulmonary arterial sildenafil or tadalafil for the for the treatment of pulmonary hypertension treatment of pulmonary arterial arterial hypertension co-administered Sildenafil hypertension and boosted darunavir with boosted darunavir has not been Tadalafil may increase plasma concentrations established. There is an increased of sildenafil or tadalafil. potential for sildenafil-associated (CYP3A inhibition) adverse events (including visual disturbances, hypotension, prolonged erection and syncope). Therefore, co- administration of boosted darunavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with boosted darunavir is not recommended. PROTON PUMP INHIBITORS Omeprazole # darunavir AUC ↔ Boosted darunavir can be co- 20 mg once daily # darunavir Cmin ↔ administered with proton pump # darunavir Cmax ↔ inhibitors without dose adjustments. SEDATIVES/HYPNOTICS Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is recommended Clorazepate extensively metabolised by when co-administering boosted Diazepam CYP3A. Co-administration with darunavir with these Estazolam boosted darunavir may cause a sedatives/hypnotics and a lower dose Flurazepam large increase in the concentration of the sedatives/hypnotics should be Midazolam (parenteral) of these medicines. considered. Zolpidem If parenteral midazolam is co- If parenteral midazolam is co- administered with boosted administered with boosted darunavir, darunavir it may cause a large it should be done in an intensive care increase in the concentration of this unit (ICU) or similar setting, which benzodiazepine. Data from ensures close clinical monitoring and concomitant use of parenteral appropriate medical management in midazolam with other protease case of respiratory depression and/or inhibitors suggest a possible 3-4 prolonged sedation. Dose adjustment fold increase in midazolam plasma for midazolam should be considered, levels. especially if more than a single dose of midazolam is administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 6377f4fd304b9d7c6481847fbb0c450071fb1a4848818644923dd1099047eab9 · Zeichen 69529–73658 im Abschnitt

Wechselwirkungen · Symtuza

Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18

HOS-138500 · Präparat HOS-098200

17 PROTON PUMP INHIBITORS Dexlansoprazole Based on theoretical Symtuza can be co-administered Esomeprazole considerations, no mechanistic with proton pump inhibitors Lansoprazole interaction is expected. without dose adjustments. Omeprazole Pantoprazole Rabeprazole SEDATIVES/HYPNOTICS Buspirone Based on theoretical considerations Clinical monitoring is Clorazepate DRV/COBI is expected to increase recommended when Diazepam these sedative/hypnotic plasma co-administering Symtuza with Estazolam concentrations. these sedatives/hypnotics and a Flurazepam (CYP3A inhibition) lower dose of the Midazolam (parenteral) sedative/hypnotic should be Zolpidem considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) estazolam (HOS-086165) esomeprazole (HOS-087944) pantoprazole (HOS-085167) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) dexlansoprazole (HOS-138501) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d66918b1ab817bed50d64727b6ed8e70c3661e6e6c213975acff37740c998350 · Zeichen 42940–44015 im Abschnitt

Wechselwirkungen · Slenyto

Slenyto 1 mg prolonged-release tablets Slenyto 5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4–5

HOS-138603 · Präparat HOS-098224

4 Benzodiazepines/non-benzodiazepine hypnotics Melatonin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics, such as zaleplon, zolpidem and zopiclone. In a clinical trial, there was clear evidence for a transitory pharmacodynamic interaction between melatonin and zolpidem one hour following co-dosing. Concomitant administration resulted in increased impairment of attention, memory and co-ordination compared to zolpidem alone. Combination with benzodiazepines and non-benzodiazepine hypnotics should be avoided.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zolpidem (HOS-086327) zaleplon (HOS-115822) zopiclone (HOS-115824)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-10T15:35:00Z · SHA-256 17494391b1b166184a1056469270f628e4597dda5631ec4cd470a78d59405d08 · Passage 4030e09921f15cfc2b565686662ef4ed7fd3acf8b7b6bbc320473c2dbdac1552 · Zeichen 898–1450 im Abschnitt

Wechselwirkungen · Xenleta

Xenleta 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7

HOS-144139 · Präparat HOS-099116

(Inhibition of CYP3A4) HIV-ANTIVIRAL AGENTS Efavirenz * Not studied Co-administration of 600 mg once daily Expected ↓ moderate CYP3A Lefamulin inducers may result in (Moderate reduced therapeutic induction of effect of lefamulin and CYP3A4) is contraindicated (see section 4.3). BENZODIAZEPINE BZ1 RECEPTOR ANTAGONIST Zolpidem* Not studied Monitor for adverse 10 mg single dose Expected ↑ reactions during co- Zolpidem administration with (Inhibition of lefamulin. Consider CYP3A4) dosage adjustment of zolpidem#. 6 Medicinal product by therapeutic Effect on areas/possible medicinal Cmax AUC Clinical comments mechanism of product levels interaction GASTRIC ACID SUPPRESSORS/NEUTRALIZERS Omeprazole Not studied No dose adjustment Expected: ↔ Lefamulin required. HERBAL PRODUCTS St. John’s Wort Not studied Co-administration of Expected: ↓ Lefamulin strong CYP3A inducers (Strong induction of may result in reduced CYP3A4) therapeutic effect of lefamulin and is contraindicated (see section 4.3). HMG-COA REDUCTASE INHIBITORS Rosuvastatin Not studied Use with caution. 20 mg single dose Atorvastatin, Lovastatin, Pravastatin

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) zolpidem (HOS-086327) efavirenz (HOS-087947) pravastatin (HOS-086306) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-05-27T10:05:00Z · SHA-256 5734c7cd97e8e3d573c5607510d56959d70dd1959b95f4adae73fc0a0a5dd6b3 · Passage 3ffc1a58bc59dcb4cad998eb13febe4e901d3dfe62b9c34fff0cfbb0509ea582 · Zeichen 7236–9810 im Abschnitt

Wechselwirkungen · Xenleta

Xenleta 150 mg concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 19

HOS-144174 · Präparat HOS-099116

(Inhibition of CYP3A4) HIV-ANTIVIRAL AGENTS Efavirenz * Not studied Co-administration of 600 mg once daily Expected moderate CYP3A ↓ Lefamulin inducers may result in (Moderate reduced therapeutic induction of effect of lefamulin and CYP3A4) is contraindicated (see section 4.3). BENZODIAZEPINE BZ1 RECEPTOR ANTAGONIST Zolpidem* Not studied No dose adjustment 10 mg single dose Expected required. — Zolpidem (Inhibition of CYP3A4) HERBAL PRODUCTS Medicinal product by therapeutic Effect on areas/possible medicinal Cmax AUC Clinical comments mechanism of product levels interaction

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zolpidem (HOS-086327) efavirenz (HOS-087947)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-05-27T10:05:00Z · SHA-256 5734c7cd97e8e3d573c5607510d56959d70dd1959b95f4adae73fc0a0a5dd6b3 · Passage ae889c3e700f38e07bf0268e492cd696c4efd2d758c2b76af1276693bd1fc0d7 · Zeichen 5672–6769 im Abschnitt

Wechselwirkungen · Enzalutamide Viatris

Enzalutamide Viatris 40 mg film-coated tablets Enzalutamide Viatris 80 mg film-coated tablets Enzalutamide Viatris 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-152525 · Präparat HOS-100781

Groups of medicinal products that can be affected include, but are not limited to: • Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-23T15:00:00Z · SHA-256 9ec2075aeb7a3bf9d945f1434168aa948ef3cdae81a1cefa92c76a3324997d49 · Passage bfc103097c88d7d8aeea8e7e62639ae12301bc9736ef551eb28e5ea67198b6ec · Zeichen 3904–4850 im Abschnitt

Quellenpassagen (18)

Wechselwirkungen · Norvir

Wechselwirkungen · Norvir

Wechselwirkungen · Xyrem

Wechselwirkungen · Circadin

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Xtandi

Wechselwirkungen · Xtandi

Wechselwirkungen · Zydelig

Wechselwirkungen · Genvoya

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Wechselwirkungen · Symtuza

Wechselwirkungen · Slenyto

Wechselwirkungen · Xenleta

Wechselwirkungen · Xenleta

Wechselwirkungen · Enzalutamide Viatris